​

Forte Biosciences Stock (NASDAQ:FBRX)

ForecastRevenueOwnershipFinancialsChart
Forte Biosciences by TradingView

Previous Close

$19.09

52W Range

$4.90 - $28.68

50D Avg

$14.57

200D Avg

$10.73

Market Cap

$229.37M

Avg Vol (3M)

$103.16K

Beta

3.30

Div Yield

-

FBRX Company Profile

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

14

IPO Date

Apr 13, 2017

Website

FBRX Performance

FBRX Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-36.60M$-32.49M$-13.90M
Net Income$-35.48M$-31.48M$-13.86M
EBITDA$-36.60M$-32.48M$-13.90M
Basic EPS$-12.17$-24.92$-19.96
Diluted EPS$-12.17$-24.92$-19.96

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q1 21May 11, 21 | 4:30 PM

Peer Comparison

TickerCompany
ACTUActuate Therapeutics Inc
CRBPCorbus Pharmaceuticals Holdings, Inc.
MOLNMolecular Partners AG
ALECAlector, Inc.
CRDFCardiff Oncology, Inc.
NKTXNkarta, Inc.
FATEFate Therapeutics, Inc.
APLTApplied Therapeutics, Inc.
ELTXElicio Therapeutics, Inc.
PEPGPepGen Inc.